SmartAI Drive Safety Tool for Real-Time Drug-Use Detection
Official title: SmartDrive: AI-Powered Mobile App for Real-Time Detection of Non-Disordered Drug Use in Drivers
Funded at Tibbling Technologies LLC · NIH-11239715 · Data updated 2026-11-12
A real-time, AI-powered mobile app helps drivers check if they might be under the influence of non-disordered drugs before they drive, with a focus on school and college bus drivers.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tibbling Technologies LLC NIH-funded |
| Lab location | 1 site (Redmond, United States) |
| Project start | June 1, 2026 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $400,000 |
| NIH project number | 1R43DA064222-01 |
| Project ID | NIH-11239715 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are school or college bus drivers and other commercial drivers who operate vehicles and could benefit from safety screening.
✕Less likely to help
Drivers not using such apps or those with no access to compatible devices may not benefit.
What this research studies
This project develops a real-time mobile app that uses cloud-based AI to assess whether a driver may be under the influence, helping promote safer driving. It analyzes facial and body pose features with a transformer-based framework and provides immediate feedback on fitness to drive. The system also connects with school or college administration and, when appropriate, authorities, to support safety decisions. The app is designed to be scalable and accessible across devices, aiming to reduce drug-influenced driving incidents among youth-transport workers.
Why it matters
Potential benefit: If successful, the app could improve road safety by enabling early identification of impaired drivers and prompting timely safety actions.
How similar studies have gone: Previous AI-driven safety tools show promise, but this is an early-stage deployment aimed at real-time in-vehicle use.
Where this research is happening
-
Tibbling Technologies LLC
Redmond, United States Active
Researchers
- Principal investigator: Iqbal, Asim — Tibbling Technologies LLC
- Study coordinator: Iqbal, Asim
Related research
Other NIH-funded projects on the same topics.
-
Couples-based motivational interviewing to reduce drug use and HIV risk in vulnerable male couples
A couples-focused program helps at-risk male couples reduce drug use and HIV risk together.
-
How growing up poor in rural Georgia affects children's brains and risk for drug use
This project looks at how early poverty and stress in rural Georgia change children's brain systems and their later chances of using drugs.
-
Understanding why teens relapse after treatment and how to keep them safe
A teen-focused study will look at why adolescents who finish inpatient treatment sometimes return to high-risk drug use and how that affects overdose risk.
-
Peer-led intervention to spread overdose prevention and support quitting opioids in high-risk communities
A randomized trial will test a peer-education program to reduce overdoses and help people who use opioids start or stay in treatment, by using social networks and new withdrawal-focused strategies.
-
High-Dose Medications for Opioid Use Disorder and Retention in Care
This project tests whether adjusted, higher-dose MOUD regimens can help people stay in treatment and reduce overdose risks during the fentanyl crisis.
-
OVAL: How laws about drug use in pregnancy affect pregnant and new mothers who use drugs
A nationwide project is looking at how laws about drug use in pregnancy influence health for pregnant and postpartum women who use drugs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.